Early treatment of Favipiravir in COVID-19 patients without pneumonia: a multicentre, open-labelled, randomized control study

References

• Organization WH. WHO Coronavirus (COVID-19) Dashboard 2022. Available from: https://covid19.who.int/
   Google Scholar
• Kutsuna S. Coronavirus disease 2019 (COVID-19): research progress and clinical practice. Glob Health Med. 2020;2(2):78–88.
   PubMedGoogle Scholar
• Chen PJ, Chao CM, Lai CC. Clinical efficacy and safety of favipiravir in the treatment of COVID-19 patients. J Infect. 2021;82(5):186–230.
   PubMed Web of Science ®Google Scholar
• Cai Q, Yang M, Liu D, et al. Experimental treatment with Favipiravir for COVID-19: an open-label control study. Engineering (Beijing). 2020;6(10):1192–1198.
   PubMedGoogle Scholar
• Pongpirul WA, Wiboonchutikul S, Charoenpong L, et al. Clinical course and potential predictive factors for pneumonia of adult patients with Coronavirus Disease 2019 (COVID-19): A retrospective observational analysis of 193 confirmed cases in Thailand. PLoS Negl Trop Dis. 2020;14(10):e0008806.
   PubMed Web of Science ®Google Scholar
• Joshi S, Parkar J, Ansari A, et al. Role of favipiravir in the treatment of COVID-19. Int J Infect Dis. 2021;102:501–508.
   PubMed Web of Science ®Google Scholar
• Alene M, Yismaw L, Assemie MA, et al. Magnitude of asymptomatic COVID-19 cases throughout the course of infection: a systematic review and meta-analysis. PLoS One. 2021;16(3):e0249090.
   PubMed Web of Science ®Google Scholar
• Doi Y, Hibino M, Hase R, et al. A prospective, randomized, open-label trial of early versus late Favipiravir therapy in hospitalized patients with COVID-19. Antimicrob Agents Chemother. 2020;64(12):e01897–20.
   PubMed Web of Science ®Google Scholar
• Udwadia ZF, Singh P, Barkate H, et al. Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: a randomized, comparative, open-label, multicenter, phase 3 clinical trial. Int J Infect Dis. 2021;103:62–71.
   PubMed Web of Science ®Google Scholar
• Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601–615.
   PubMed Web of Science ®Google Scholar
• Eroglu E, Toprak C. Overview of favipiravir and remdesivir treatment for COVID-19. Int J Pharm Sci Res. 2021;12(4):1950–1957.
   Google Scholar
• Kumari P, Rawat K, Saha L. Pipeline pharmacological therapies in clinical trial for COVID-19 pandemic: a recent update. Curr Pharmacol Rep. 2020;6(5):228–240.
   PubMedGoogle Scholar
• Manabe T, Kambayashi D, Akatsu H, et al. Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis. BMC Infect Dis. 2021;21(1):489.
   PubMed Web of Science ®Google Scholar
• Wei FF, Moradkhani A, Hezaveh HH, et al. Evaluating the treatment with Favipiravir in patients infected by COVID-19: A systematic review and meta-analysis. Int J Sci Res Dental Med Sci. 2020;2(3):87–91.
   Google Scholar
• Kelleni MT. Tocilizumab, Remdesivir, Favipiravir, and Dexamethasone Repurposed for COVID-19: a comprehensive clinical and pharmacovigilant reassessment. SN Compr Clin Med. 2021;3(4):919–923.
   PubMedGoogle Scholar
• Ko M, Jeon S, Ryu WS, et al. Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells. J Med Virol. 2021;93(3):1403–1408.
   PubMed Web of Science ®Google Scholar
• Sreekanth Reddy O, Lai WF. Tackling COVID-19 using Remdesivir and Favipiravir as therapeutic options. Chembiochem. 2021;22(6):939–948.
   PubMed Web of Science ®Google Scholar
• Shrestha DB, Budhathoki P, Khadka S, et al. Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis. Virol J. 2020;17(1):141.
   PubMed Web of Science ®Google Scholar
• Gottlieb RL, Vaca CE, Paredes R, et al. Early Remdesivir to prevent progression to severe Covid-19 in outpatients. N Engl J Med. 2022;386(4):305–315.
   PubMed Web of Science ®Google Scholar
• Thorlund K, Sheldrick K, Mills E. Molnupiravir for Covid-19 in nonhospitalized patients. N Engl J Med. 2022;386(13):e32.
   PubMedGoogle Scholar
• Brophy JM. Molnupiravir’s authorisation was premature. BMJ. 2022;376:o443.
   Google Scholar
• Bernal A J, da Silva MM G, Musungaie DB, et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N Engl J Med. 2022;386(6):509–520.
   PubMed Web of Science ®Google Scholar
• Seneviratne SL, Abeysuriya V, De Mel S, et al. Favipiravir in COVID-19. Int J Progressive Sci Technol. 2020;19(2):143–145.
   Google Scholar
• Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci. 2017;93(7):449–463.
   PubMed Web of Science ®Google Scholar
• Agrawal U, Raju R, Udwadia ZF. Favipiravir: A new and emerging antiviral option in COVID-19. Med J Armed Forces India. 2020;76(4):370–376.
   PubMedGoogle Scholar
• Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–271.
   PubMed Web of Science ®Google Scholar
• Ivashchenko AA, Dmitriev KA, Vostokova NV, et al. AVIFAVIR for treatment of patients with moderate Coronavirus disease 2019 (COVID-19): interim results of a phase II/III multicenter randomized clinical trial. Clin Infect Dis. 2021;73(3):531–534.
   PubMed Web of Science ®Google Scholar
• Yanai H. Favipiravir: a possible pharmaceutical treatment for COVID-19. J Endocrinol Metab. 2020;10(2):33–34.
   Web of Science ®Google Scholar
• Holubar M, Subramanian A, Purington N, et al. Favipiravir for treatment of outpatients with asymptomatic or uncomplicated COVID-19: a double-blind randomized, placebo-controlled, phase 2 trial. Clin Infect Dis. 2022:ciac312.
   Web of Science ®Google Scholar
• Shinada K, Sato T, Moriyama S, et al. Longitudinal analysis of neutralizing potency against SARS-CoV-2 in the recovered patients after treatment with or without Favipiravir. Viruses. 2022;14(4):670.
   PubMed Web of Science ®Google Scholar
• Özlüşen B, Kozan Ş, Akcan RE, et al. Effectiveness of favipiravir in COVID-19: a live systematic review. Eur J Clin Microbiol Infect Dis. 2021;40(12):2575–2583.
   PubMed Web of Science ®Google Scholar
• Siemieniuk RA, Bartoszko JJ, Ge L, et al. Drug treatments for covid-19: living systematic review and network meta-analysis. Br Med J. 2020;370:m2980.
   PubMed Web of Science ®Google Scholar
• Hassanipour S, Arab-Zozani M, Amani B, et al. The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials. Sci Rep. 2021;11(1):11022.
   PubMed Web of Science ®Google Scholar
• Pilkington V, Pepperrell T, Hill A. A review of the safety of favipiravir – a potential treatment in the COVID-19 pandemic? J Virus Erad. 2020;6(2):45–51.
   PubMed Web of Science ®Google Scholar
• FUJIFILM Toyama Chemical Co. L. Notice of the new drug application approval of “AVIGAN® Tablet 200mg” in Japan for the anti-influenza virus drug 2014. Available from: https://www.cdc.gov.tw/File/Get/ht8jUiB_MI-aKnlwstwzvw
   Google Scholar
• Prasithsirikul W, Pongpirul K, Sakornsakolpat P, et al. Adjunctive favipiravir for severe COVID-19: a retrospective observational study of the first 41 patients in Thailand. Asian Biomed (Res Rev News). 2020;14(3):107–110.
   Google Scholar
• Mendenhall M, Russell A, Smee DF, et al. Effective oral favipiravir (T-705) therapy initiated after the onset of clinical disease in a model of arenavirus hemorrhagic fever. PLoS Negl Trop Dis. 2011;5(10):e1342.
   PubMed Web of Science ®Google Scholar
• Oestereich L, Lüdtke A, Wurr S, et al. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Res. 2014;105:17–21.
   PubMed Web of Science ®Google Scholar
• Gowen BB, Wong MH, Jung KH, et al. In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. Antimicrob Agents Chemother. 2007;51(9):3168–3176.
   PubMed Web of Science ®Google Scholar
• Bai CQ, Mu JS, Kargbo D, et al. Clinical and virological characteristics of Ebola virus disease patients treated With favipiravir (T-705)-Sierra Leone, 2014. Clin Infect Dis. 2016;63(10):1288–1294.
   PubMed Web of Science ®Google Scholar
• Lu CC, Chen MY, Lee WS, et al. Potential therapeutic agents against COVID-19: what we know so far. J Chin Med Assoc. 2020;83(6):534–536.
   PubMed Web of Science ®Google Scholar
• Baranovich T, Wong SS, Armstrong J, et al. T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro. J Virol. 2013;87(7):3741–3751.
   PubMed Web of Science ®Google Scholar
• Sheahan TP, Sims AC, Zhou S, et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med. 2020;12(541):eabb5883.
   PubMed Web of Science ®Google Scholar
• Sawanpanyalert N, Sirijatuphat R, Sangsayunh P, et al. Assessment of outcomes following implementation of antiviral treatment guidelines for COVID-19 during the first wave in Thailand. Southeast Asian J Trop Med Public Health. 2021;52(4):572–585.
   Web of Science ®Google Scholar
• Fujii S, Ibe Y, Ishigo T, et al. Early favipiravir treatment was associated with early defervescence in non-severe COVID-19 patients. J Infect Chemother. 2021;27(7):1051–1057.
   PubMed Web of Science ®Google Scholar
• Ghasemnejad-Berenji M, Pashapour S. Favipiravir and COVID-19: a simplified summary. Drug Res (Stuttg). 2021;71(3):166–170.
   PubMedGoogle Scholar
• Srinivas P, Sacha G, Koval C. Antivirals for COVID-19. Cleaveland Clin J Med. 2020.
   PubMed Web of Science ®Google Scholar
• Medical Research Foundation T. Thai clinical trials registry 2021. Available from: https://thaiclinicaltrials.org/
   Google Scholar
• Health Do. National early warning score: National clinical guideline No. 1 2013.
   Google Scholar
• Wichukchinda N, Bunnueang N, Inunchot W, et al. Establishment of SARS-CoV-2 quantification by reverse transcription droplet digital PCR. Bull Dep Med Sci. 2021;62(3):194–204.
   Google Scholar
• Considerations for the use of saliva as sample material for COVID-19 testing. European Centre for Disease Prevention and Control; 2021. Available from: https://www.ecdc.europa.eu/en/publications-data/considerations-use-saliva-sample-material-covid-19-testing
   Google Scholar
• Prakash A, Singh H, Kaur H, et al. Systematic review and meta-analysis of effectiveness and safety of favipiravir in the management of novel coronavirus (COVID-19) patients. Indian J Pharmacol. 2020;52(5):414–421.
   PubMed Web of Science ®Google Scholar
• Manosuthi W, Jeungsmarn S, Okada P, et al. Nasopharyngeal SARS-CoV-2 viral load response among COVID-19 patients receiving Favipiravir. Jpn J Infect Dis. 2021;74(5):416–420.
   PubMed Web of Science ®Google Scholar
• Deng W, Yang C, Yang S, et al. Evaluation of favipiravir in the treatment of COVID-19 based on the real-world. Expert Rev Anti Infect Ther. 2022;20(4):555–565.
   PubMed Web of Science ®Google Scholar
• Fischer WA, Eron JJ, Holman W, et al. A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus. Sci Transl Med. 2022;14(628):eabl7430.
   PubMed Web of Science ®Google Scholar
• Ader F, Bouscambert-Duchamp M, Hites M, et al. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. Lancet Infect Dis. 2022;22(2):209–221.
   PubMed Web of Science ®Google Scholar
• Chuah CH, Chow TS, Hor CP, et al. Efficacy of early treatment with Favipiravir on disease progression among high risk COVID-19 patients: a randomized, open-label clinical trial. Clin Infect Dis. 2021;75(1):e432–e439.
   Web of Science ®Google Scholar
• 35 generic manufacturers sign agreements with MPP to produce low-cost, generic versions of Pfizer’s oral COVID-19 treatment nirmatrelvir in combination with ritonavir for supply in 95 low- and middle-income countries [Internet]. Medicines Patent Pool; 2022. Available from: https://medicinespatentpool.org/news-publications-post/35-generic-manufacturers-sign-agreements-with-mpp-to-produce-low-cost-generic-versions-of-pfizers-oral-covid-19-treatment-nirmatrelvir-in-combination-with-ritonavir-for-supply-in-95-low-and
   Google Scholar
• 27 generic manufacturers sign agreements with MPP to produce low-cost versions of COVID-19 antiviral medication molnupiravir for supply in 105 low- and-middle-income countries [Internet]. Medicines Patent Pool; 2022. Available from: https://medicinespatentpool.org/news-publications-post/27-generic-manufacturers-sign-agreements-with-mpp-to-produce-molnupiravir
   Google Scholar
• Pertinez H, Rajoli RKR, Khoo SH, et al. Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5'-triphosphate exposure to support posology for SARS-CoV-2. J Antimicrob Chemother. 2021;76(8):2121–2128.
   PubMed Web of Science ®Google Scholar